Equities

Neurosense Therapeutics Ltd

  • Add to watchlist
  • Add to portfolio
  • Add an alert
NRSN:NAQ

Neurosense Therapeutics Ltd

Actions
  • Price (USD)1.04
  • Today's Change0.04 / 4.00%
  • Shares traded158.28k
  • 1 Year change-11.11%
  • Beta1.5778
Data delayed at least 15 minutes, as of Feb 13 2026 21:00 GMT.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

NeuroSense Therapeutics Ltd is an Israel-based clinical-stage pharmaceutical company. The Company is active in field of drug development and treatment offers Amyotrophic Lateral Sclerosis (ALS) patients, as well as other neurodegenerative diseases. The Company's lead product candidate, PrimeC, is an oral formulation of a fixed dose combination composed of a specific ratio of drugs. In addition to PrimeC, the Company has initiated research and development efforts in Alzheimer's disease and Parkinson's disease

  • Revenue in USD (TTM)0.00
  • Net income in USD-8.66m
  • Incorporated2017
  • Employees15.00
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Passage Bio Inc0.00-45.26m28.00m60.00--0.8999-----14.47-14.470.009.790.00----0.00-48.69-49.32-61.70-53.58------------0.00------36.54---54.23--
AN2 Therapeutics Inc0.00-33.99m29.05m22.00--0.4805-----1.13-1.130.002.210.00----0.00-41.21-53.41-45.91-58.50------------0.00------20.72------
Rein Therapeutics Inc0.00-58.89m29.44m11.00--23.76-----2.63-2.630.001.840.00----0.00-74.57-64.62-80.38-71.24------------0.00-------299.71------
Harvard Apparatus Regenertv Tchnlgy Inc743.00k-6.53m29.53m8.00--19.00--39.75-0.4029-0.40290.04590.09050.18919.21371.5092,875.00-166.09-292.39-227.59-1,068.0616.29---878.20-6,677.861.83--0.00--317.48--14.30------
Dyadic International Inc3.34m-7.35m30.04m6.00--11.52--8.99-0.2371-0.23710.10770.0720.2974--5.27557,033.30-65.38-46.12-89.89-51.9631.5435.01-219.86-335.59---34.440.6579--20.5815.7714.51------
Lantern Pharma Inc0.00-18.92m30.20m24.00--3.11-----1.75-1.750.000.86840.00----0.00-86.16-32.94-104.31-34.72------------0.00-------30.20--17.11--
Reviva Pharmaceuticals Holdings Inc0.00-22.76m30.45m14.00--5.52-----0.4722-0.47220.000.04720.00----0.00-207.23------------------0.00------23.79------
Neurosense Therapeutics Ltd0.00-8.66m30.89m15.00---------0.361-0.3610.00-0.02110.00----0.00-491.23-145.64---198.79---------------------1.02---15.59--
Palatin Technologies Inc8.85m-4.81m31.07m29.00--42.71--3.51-13.52-13.5212.390.40731.47----305,087.90-79.90-79.95---118.700.0091.70-54.32-1,326.05----0.00---100.00--41.80------
Tempest Therapeutics Inc0.00-36.05m31.14m24.00--1.65-----10.40-10.400.001.430.00----0.00-141.49-63.01-215.46-80.57------------0.00-------41.88--1.85--
Werewolf Therapeutics Inc0.00-72.84m31.73m39.00--1.04-----1.62-1.620.000.62640.00----0.00-66.32-33.10-76.84-36.81-------593.05---54.290.4829---90.55---88.70---0.919--
Jasper Therapeutics Inc0.00-91.02m31.90m64.00--2.76-----5.90-5.900.000.41350.00----0.00-116.04-75.11-147.54-86.11------------0.00-------10.55------
Atara Biotherapeutics Inc151.93m23.40m32.09m38.002.03--1.210.21122.192.1912.81-5.081.763.9993.55993,006.6027.07-67.79---93.0781.63--15.40-558.471.0215.248.31--1,404.02--69.07---46.73--
Onkure Therapeutics Inc0.00-81.21m32.79m46.00--0.4936-----12.78-12.780.004.900.00----0.00-107.93-48.73-115.20-53.34------------0.00------31.94--49.34--
Promis Neurosciences Inc0.00-29.28m32.82m6.00--3.57-----18.62-18.620.004.270.00-------127.41-85.65-188.18-145.08-------3,184,250.00----0.00------121.03------
Bioqual Inc46.54m453.25k33.55m108.0074.020.93812.220.72090.50680.506852.0339.990.7111--3.19--0.69264.120.77454.8312.8516.150.9744.03----0.0032.81-16.601.06-316.79---36.99-6.51
Data as of Feb 13 2026. Currency figures normalised to Neurosense Therapeutics Ltd's reporting currency: US Dollar USD

Institutional shareholders

1.01%Per cent of shares held by top holders
HolderShares% Held
Yorkville Advisors Global LPas of 31 Dec 2025100.00k0.34%
Meitav Mutual Funds Ltd.as of 31 Dec 202540.00k0.14%
GTS Securities LLCas of 31 Dec 202535.75k0.12%
Commonwealth Equity Services LLCas of 31 Dec 202522.78k0.08%
Two Sigma Investments LPas of 30 Sep 202521.09k0.07%
Squarepoint OPS LLCas of 31 Dec 202517.93k0.06%
UBS Securities LLCas of 31 Dec 202517.10k0.06%
Pathstone Family Office LLCas of 31 Dec 202516.53k0.06%
Geode Capital Management LLCas of 31 Dec 202515.87k0.05%
UBS Switzerland AG (Investment Management)as of 31 Dec 202513.77k0.05%
More ▼
Data from 30 Sep 2025 - 31 Dec 2025Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.